Ethical issues in funding orphan drug research and development.
about
CRISPR/Cas9 and mitochondrial gene replacement therapy: promising techniques and ethical considerationsThe legal imperative for treating rare disorders.Reimbursement of orphan drugs in Belgium: what (else) matters?Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.Rare diseases: Canada's "research orphans".Drugs for exceptionally rare diseases: do they deserve special status for funding?Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?Should EOAD patients be included in clinical trials?Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey.Our moral obligations in caring for patients with orphan cancers.When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada.The Role of Solidarity(-ies) in Rare Diseases Research.Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.Les cancers orphelins et nos obligations morales.Ethical issues in health research in children
P2860
Q28073860-840743D1-75CA-445A-A0D8-21B3FCD7B09EQ30577814-B5D7EC46-CD86-4C59-9587-16A5ACA9C738Q30587491-031D39C2-83E3-46DC-BF02-D17F4538C9A0Q33568653-22CAAB75-374F-40DB-A824-E7E481878541Q35835153-7C998BB3-72B6-4BCB-B93C-148F7D7F5971Q35896334-FE28D3AD-232D-4B56-8225-AB0A26B8FB1EQ36276435-0BE6BE7F-C075-4270-A19F-407601C72BA1Q37566934-D436C9DF-B5FF-42FC-8F9B-F04BC0DD0A76Q37846246-9FF16D83-461A-4B31-87EA-F558CD11A718Q41585720-D74BD595-8FCD-470E-9E7B-A30109BBB519Q42988912-E85ABBAF-728E-47B5-8D4B-2CA023737814Q45754296-3C4E5192-60D0-40B9-833E-10FCC3EF1D66Q45951404-599BD68B-FC9C-4A2E-B46B-088D2D428E93Q45960757-4113ED1D-1AF4-4EC8-870C-28DB8247BA4AQ46423272-9493B812-7377-4BE6-8155-C4406604B162Q56783697-EFD3009F-2DE3-4D51-A06F-435CC5A14203
P2860
Ethical issues in funding orphan drug research and development.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Ethical issues in funding orphan drug research and development.
@ast
Ethical issues in funding orphan drug research and development.
@en
type
label
Ethical issues in funding orphan drug research and development.
@ast
Ethical issues in funding orphan drug research and development.
@en
prefLabel
Ethical issues in funding orphan drug research and development.
@ast
Ethical issues in funding orphan drug research and development.
@en
P2860
P356
P1476
Ethical issues in funding orphan drug research and development
@en
P2093
P2860
P304
P356
10.1136/JME.2003.007138
P577
2005-03-01T00:00:00Z